By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 153.43 |
| Closing Price Change | $ 4.10 |
| % Change | 0.00 % |
| 52 Week High | $0.00 |
| 52 Week Low | $0.00 |
| Volume | 0 |
| Shares Issued | 145.80m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 5 |
| Neutral | 21 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 34 |

You are here: research